Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine.
Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.